Gustavo Baldassarre
Overview
Explore the profile of Gustavo Baldassarre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
2632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scafetta G, Rampioni Vinciguerra G, Giglio S, Faruq O, Cirombella R, Segatto I, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):96.
PMID: 40082972
Breast cancer ranks as the most prevalent form of cancer globally. Currently, advanced screening methods have significantly improved early detection rates. These achievements have led to more non-invasive cancer diagnoses...
2.
Spessotto P, Clemente N, Mongiat M, Capuano A, Baldassarre G, Polesel J, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):101626.
PMID: 39964817
Objective: Probe-based confocal laser endomicroscopy (pCLE) is a novel real-time imaging technique that is potentially useful for accurately distinguishing between normal and cancerous tissues. The aim of this study was...
3.
Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):11.
PMID: 39800748
Cyclin Dependent Kinases (CDKs) are closely connected to the regulation of cell cycle progression, having been first identified as the kinases able to drive cell division. In reality, the human...
4.
Schiappacassi M, Spizzo R, Polesel J, Musco L, Doliana R, Pellizzari L, et al.
Transl Oncol
. 2024 Dec;
51:102221.
PMID: 39616986
Background And Purpose: Head and Neck Squamous Cell Cancer (HNSCC) originates from the oral cavity, oropharynx, hypopharynx and larynx, and it ranks sixth among global cancers. Despite modest 5-year survival...
5.
Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra G, Karimbayli J, et al.
Sci Adv
. 2024 Nov;
10(46):eadp6567.
PMID: 39536107
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic...
6.
Segatto I, Mattevi M, Rampioni Vinciguerra G, Crestan N, Musco L, Favero A, et al.
J Pathol
. 2024 Oct;
264(4):434-447.
PMID: 39449657
Breast cancer (BC) is marked by significant genetic, morphological and clinical heterogeneity. To capture this heterogeneity and unravel the molecular mechanisms driving tumor progression and drug resistance, we established a...
7.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1981.
PMID: 38997596
No abstract available.
8.
Karimbayli J, Pellarin I, Belletti B, Baldassarre G
Mol Cancer
. 2024 Jul;
23(1):135.
PMID: 38951876
In cells, signal transduction heavily relies on the intricate regulation of protein kinases, which provide the fundamental framework for modulating most signaling pathways. Dysregulation of kinase activity has been implicated...
9.
Capuano A, Vescovo M, Canesi S, Pivetta E, Doliana R, Nadin M, et al.
Gastric Cancer
. 2024 Jun;
27(5):1016-1030.
PMID: 38941035
Background: The contribution of the tumor microenvironment and extracellular matrix to the aggressive biology of Gastric Cancer (GC) has been recently characterized; however, the role of EMILIN-1 in this context...
10.
Rodman E, Emch M, Hou X, Bajaj A, Pearson N, John A, et al.
bioRxiv
. 2024 Jun;
PMID: 38895264
Statement Of Significance: Lestaurtinib is a novel inhibitor of ovarian cancer, including chemotherapy- and PARPi-resistant models, that acts through robust inhibition of the JAK/STAT pathway and synergizes with standard-of-care agents...